1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,280 | 2,500 | 07.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* INDICATIVE ANNOUNCEMENT ON THE CHANGE IN EQUITY OF THE SHAREHOLDERS ... | 1 | HKEx | ||
| 29.05. | JUNSHI BIO (01877): FORM OF PROXY FOR THE 2024 ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 20 JUNE 2025 | 3 | HKEx | ||
| 29.05. | JUNSHI BIO (01877): 2024 ANNUAL REPORTS AND ACCOUNTS 2024 PROFIT DISTRIBUTION PLAN CREDIT LINES FROM FINANCIAL INSTITUTION(S) FOR 2025 DIRECTORS' AND ... | - | HKEx | ||
| SHANGHAI JUNSHI BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 29.05. | JUNSHI BIO (01877): NOTICE OF THE 2024 ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 29.05. | JUNSHI BIO (01877): CLOSURE OF REGISTER OF MEMBERS OF H SHARES | 1 | HKEx | ||
| 29.05. | JUNSHI BIO (01877): ANNOUNCEMENT - ADJUSTMENTS TO THE USE OF PROCEEDS FROM THE 2022 ISSUANCE OF A SHARES | - | HKEx | ||
| 29.05. | No. of COVID-19 Cases Hikes, Triggering Speculation in Related Pharma; CSPC PHARMA/JUNSHI BIO/SIMCERE PHARMA/BRII-B Surge 10%+ | 8 | AASTOCKS | ||
| 27.05. | Junshi Biosciences Announces Ongericimab's sNDA Approval in China | 325 | GlobeNewswire (Europe) | SHANGHAI, May 27, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the... ► Artikel lesen | |
| 27.05. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - APPROVAL OF THE SUPPLEMENTAL NEW DRUG APPLICATION FOR ONGERICIMAB INJECTION | 3 | HKEx | ||
| 20.05. | SIMCERE PHARMA , JUNSHI BIO Leap ~5% as COVID Activity Surges in Mainland/HK | 2 | AASTOCKS | ||
| 16.05. | JPMorgan raises Junshi Biosciences rating to neutral | 2 | Investing.com | ||
| 25.04. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 2025 FIRST QUARTERLY REPORT | 3 | HKEx | ||
| 25.04. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE PARTICIPATION IN THE 2024 ANNUAL RESULTS ... | - | HKEx | ||
| 25.04. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON APPOINTMENT OF SECURITIES AFFAIRS REPRESENTATIVE | 1 | HKEx | ||
| 25.04. | Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma | 463 | GlobeNewswire (Europe) | SHANGHAI, April 25, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to... ► Artikel lesen | |
| 25.04. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - APPROVAL OF THE SUPPLEMENTAL NEW DRUG APPLICATION FOR TORIPALIMAB AS THE FIRST-LINE TREATMENT OF MELANOMA | 2 | HKEx | ||
| 25.04. | JUNSHI BIO (01877): 2024 ANNUAL REPORT | 4 | HKEx | ||
| 11.04. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - UPDATES ON SHAREHOLDING OF SINGLE LARGEST SHAREHOLDER AND PLAN OF THE CHAIRMAN OF THE COMPANY TO INCREASE ... | - | HKEx | ||
| 10.04. | JUNSHI BIO (01877): DATE OF BOARD MEETING | - | HKEx | ||
| 31.03. | Shanghai Junshi Biosciences reports FY results | 1 | Seeking Alpha |
1 2 3 4 Weiter >>
62 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PHATHOM PHARMACEUTICALS | 8,920 | +90,19 % | Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets through May 3, 2032 | FLORHAM PARK, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) today announced that the U.S. Food and Drug Administration (FDA) has approved Phathom's Citizen Petition... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 36,240 | +1,83 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| QIAGEN | 40,060 | -0,55 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
| ARCELLX | 68,10 | +2,81 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 14,370 | +6,37 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,485 | +20,02 % | Recursion Pharmaceuticals shares surge on AI model release | ||
| TARSUS PHARMACEUTICALS | 43,920 | -0,39 % | Oppenheimer assumes Tarsus stock at outperform on strong sales | ||
| BIONTECH | 95,35 | +0,05 % | Summit Therapeutics crasht - BioNTech in Sippenhaft | Wie gewonnen, so zerronnen: Die Aktie von Summit Therapeutics brach am vergangenen Freitag an der Nasdaq um rund 30 Prozent ein. Weitere Studiendaten zum großen Hoffnungsträger Ivonescimab, den die... ► Artikel lesen | |
| VERA THERAPEUTICS | 22,760 | -25,69 % | Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy | Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 46,880 | -3,99 % | ROUNDUP/Aktien New York: Knappes Plus - Gelassenheit trotz Zoll-Unruhen | NEW YORK (dpa-AFX) - Die US-Börsen haben am Dienstag knappe Kursgewinne erzielt. Die jüngst wieder aufflackernden, internationalen Handelsstreitigkeiten wegen der amerikanischen Zollpolitik scheinen... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 15,240 | +2,83 % | RBC Capital behält Outperform-Rating für Edgewise Therapeutics-Aktie bei | ||
| JANUX THERAPEUTICS | 26,210 | +5,86 % | Leerink cuts Janux Therapeutics price target to $89, keeps Outperform | ||
| EVOTEC | 7,060 | +0,94 % | Evotec Aktie: Ohne Übernahme sieht es schlecht aus! Auf diese Kursmarke kommt es an! | © Foto: Finanznachrichten (Symbolbild)Zwischen Kursrakete mit Übernahmefantasie und Korrekturmodus Richtung Süden. Der Biotech-Titel aus Hamburg liefert seit Wochen ein Wechselbad der Gefühle. Kann... ► Artikel lesen | |
| 89BIO | 10,250 | +3,12 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization... ► Artikel lesen | |
| TREVI THERAPEUTICS | 7,060 | +4,75 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough | Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p
Patients saw a... ► Artikel lesen |
SHANGHAI JUNSHI BIOSCIENCES CO LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,020 (-0,87 %) liegt der Kurs bei 2,280 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI JUNSHI BIOSCIENCES CO LTD finden Sie auf Wallstreet Online.